A.R.T. Advisors’s Clovis Oncology, Inc. CLVS Stock Holding History

A.R.T. Advisors’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-30,434	Closed	-$453K	–	1824
2019 Q2	$453K	Buy	30,434 +17,200	+130%	+$311K	0.03%	784
2019 Q1	$328K	Buy	+13,234	New	+$332K	0.02%	902
2018 Q1	–	Sell	-25,100	Closed	-$1.71M	–	1830
2017 Q4	$1.71M	Buy	+25,100	New	+$1.75M	0.08%	423
2017 Q3	–	Sell	-54,400	Closed	-$5.09M	–	1771
2017 Q2	$5.09M	Sell	54,400 -32,800	-38%	-$2.01M	0.27%	65
2017 Q1	$5.55M	Buy	87,200 +11,500	+15%	+$699K	0.26%	84
2016 Q4	$3.36M	Buy	75,700 +42,000	+125%	+$1.48M	0.2%	127
2016 Q3	$1.21M	Buy	+33,700	New	+$723K	0.39%	49
2016 Q2	–	Sell	-283,124	Closed	-$5.43M	–	1718
2016 Q1	$5.43M	Buy	283,124 +169,273	+149%	+$3.58M	0.24%	82
2015 Q4	$3.98M	Buy	113,851 +88,947	+357%	+$5.74M	0.19%	124
2015 Q3	$2.29M	Sell	24,904 -39,470	-61%	-$3.42M	0.08%	339
2015 Q2	$5.66M	Buy	+64,374	New	+$5.51M	0.19%	125
2013 Q4	–	Sell	-17,206	Closed	-$1.05M	–	1585
2013 Q3	$1.05M	Sell	17,206 -39,125	-69%	-$2.77M	0.06%	487
2013 Q2	$3.77M	Buy	+56,331	New	+$2.53M	0.12%	231

Other funds holding CLVS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

ECP

Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return

A.R.T. Advisors's CLVS Position: Q3 2019 in Review

A.R.T. Advisors sold out of Clovis Oncology, Inc. (CLVS) in Q3 2019, closing a stake of 30,434 shares — an estimated $453K sold.

A.R.T. Advisors first reported a position in CLVS in Q2 2013 and held it in 13 quarters. The position peaked at $5.66M in Q2 2015. 153 funds tracked by Wall St. Rank hold CLVS as of Q3 2019.

A.R.T. Advisors reported no remaining Clovis Oncology, Inc. position as of Q3 2019 after selling out during the quarter.
A.R.T. Advisors sold 30,434 Clovis Oncology, Inc. shares in Q3 2019, an estimated $453K.
A.R.T. Advisors first reported a position in Clovis Oncology, Inc. in Q2 2013 and held it in 13 quarters.
A.R.T. Advisors's Clovis Oncology, Inc. position peaked at $5.66M in Q2 2015.
153 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2019.

Based on A.R.T. Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.